LONDON, UK, and MISSISSAUGA, ON, Aug. 8 /CNW/ - As part of its broad
commitment to improving access to medicines, GlaxoSmithKline today announced
it has given consent through Canada's Access to Medicines Regime to enable a
Canadian company (Apotex) to manufacture a generic fixed dose combination
(FDC) antiretroviral (ARV), containing two molecules over which GSK has patent
rights (zidovudine and lamivudine) for the treatment of HIV/AIDS in Rwanda.
Canada's Access to Medicines Regime reflects the WTO "31f" agreement of
August 2003 and enables the government to authorise the production of certain
patented medicines for export. The legislation includes controls which are
designed to ensure that these essential medicines reach the patients for whom
they are intended and the authorisation to be granted will be subject to these
controls. GSK has agreed to waive royalties on the basis that Apotex's triple
combination generic ARV will be supplied on a no profit basis.
Paul Lucas, President and CEO, GSK Canada said, "Tackling the AIDS crisis
is one of the greatest challenges the world faces. GSK continues to play its
part to tackle this crisis through research and development, not-for-profit
pricing and ongoing investment in dedicated community programmes. Our decision
to allow Apotex to manufacture an FDC containing two GSK molecules is part of
this broad commitment. It also shows that Canada's Access to Medicines Regime
operates effectively to enable supply of medicines from Canada as envisaged
under the 31f Agreement."
GlaxoSmithKline - one of the world's leading research-based
pharmaceutical and health-care companies - is committed to improving the
quality of human life by enabling people to do more, feel better and live
GSK has issued eight previously announced voluntary licences to produce
generic versions of GSK's patented HIV/AIDS medicines for patients across
Sub-Saharan Africa. In 2006 alone, GSK supplied 86 million tablets of
preferentially priced ARVs to developing countries, while over 120 million ARV
generic tablets were supplied by companies licensed by GSK.
For further information:
For further information: Peter Schram, GlaxoSmithKline Corporate
Communications, (905) 819-3363